antibiotic prophylaxis

Phase 3

AAssistance Publique - Hôpitaux de Paris

antibiotic prophylaxis is one of 29 therapeutic programs targeting Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Prostate CancerActive, not recruiting

Prostate CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

314 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Phase 3

20 2

Xaluritamig

Amgen

Phase 3

4 3

Androgen Deprivation Treatment

MMedical University of Vienna

Phase 3

1 4

Lupron Depot

RRepros Therapeutics Inc.

Phase 3

2 5

antibiotic prophylaxis

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 6

Trexall

Jazz Pharmaceuticals

Preclinical

—7

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 8

Duragesic

CCephalon

Preclinical

1 9

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 10

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

Prostate Cancer

NCT01407263

Q3 2029

Phase 3Not yet recruiting

Chimeric Antigen Receptor T-Cell

NCT07754682

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

A Randomized Trial of Modifications to Radical Prostatectomy

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT01407263·3,204 enrolled

Chimeric Antigen Receptor T-cell1 trial

A Multicentric Phase III Randomized Clinical Trial Open-label, Comparing Immunoglobulin Replacement Therapy (IgRT) and Antibiotic Prophylaxis (AP) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT07754682·228 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for antibiotic prophylaxis. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for antibiotic prophylaxis. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AAssistance Publique - Hôpitaux de Paris

antibiotic prophylaxis

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2029

Trials by Indication[1]

Prostate Cancer1 trial

Chimeric Antigen Receptor T-cell1 trial

References

Drug Info

Quick Facts

Related News